Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

A Phase 1 Study of the HSP90 Inhibitor, STA-9090, Administered Once-Weekly in Patients With Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00687934

Enrollment

Registered

2008-06-02

Start date

2007-10-31

Completion date

2011-10-31

Last updated

2014-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Keywords

metastatic cancer, solid tumor, histologically or cytologically confirmed non-hematological, malignancy that is metastatic or unresectable for which no, standard therapy exists, STA-9090, ganetespib

Brief summary

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

Interventions

DRUGSTA-9090

This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

25 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients must be documented to be refractory or not candidates for current approved therapies. * Must have an ECOG status 0-2. * Peripheral neuropathy \< or = 2. * Must have acceptable organ and marrow function per protocol parameters. * No clinically significant ventricular arrythmias or ischemia.

Exclusion criteria

* Must not be pregnant or breastfeeding. * Chemotherapy or radiation within 3 weeks. * Previous radiation to \>25% of total bone marrow. * Previous high dose chemotherapy with autologous or allogeneic hematopoietic stem cell transplantation. * Primary brain tumors or active brain metastases. * Use of any investigational agents within 4 weeks. * Treatment with chronic immunosuppressants. * Uncontrolled, intercurrent illness.

Design outcomes

Primary

Measure	Time frame
The safety and tolerability of STA-9090 (ganetespib) in cancer patients via assessment of dose limiting toxicities	Cycle 1

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 24, 2026